Schwab Charles Investment Management Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,623,639 shares of the company’s stock after purchasing an additional 473,300 shares during the period. Johnson & Johnson comprises about 1.4% of Schwab Charles Investment Management Inc.’s investment portfolio, making the stock its 4th biggest position. Schwab Charles Investment Management Inc. owned 0.43% of Johnson & Johnson worth $1,537,692,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Sumitomo Mitsui Asset Management Company LTD raised its stake in shares of Johnson & Johnson by 4.1% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 281,410 shares of the company’s stock worth $35,049,000 after acquiring an additional 11,194 shares during the last quarter. Pachira Investments Inc. raised its stake in shares of Johnson & Johnson by 12.2% in the first quarter. Pachira Investments Inc. now owns 4,424 shares of the company’s stock worth $551,000 after acquiring an additional 480 shares during the last quarter. SPC Financial Inc. raised its stake in shares of Johnson & Johnson by 3.7% in the first quarter. SPC Financial Inc. now owns 3,760 shares of the company’s stock worth $468,000 after acquiring an additional 135 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Johnson & Johnson in the first quarter worth about $5,218,000. Finally, Garland Capital Management Inc. raised its stake in shares of Johnson & Johnson by 0.4% in the first quarter. Garland Capital Management Inc. now owns 49,500 shares of the company’s stock worth $6,165,000 after acquiring an additional 200 shares during the last quarter. 65.61% of the stock is owned by hedge funds and other institutional investors.

JNJ has been the subject of a number of research analyst reports. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target for the company in a research report on Monday, October 30th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Finally, UBS AG reiterated an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $143.70.

Johnson & Johnson (NYSE:JNJ) opened at $137.29 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The firm has a market cap of $371,653.16, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 2.81 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is currently 58.33%.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Position Boosted by Schwab Charles Investment Management Inc.” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/23/johnson-johnson-jnj-position-boosted-by-schwab-charles-investment-management-inc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.